GlassScriptPhysician profile
Graham V Byrum
NPI 1174525315
$1,708.15
in general payments reported to CMS, 2019-2025
28 companies · $61.09 in 2025
The $61.09 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $284 · 2021: $177 · 2022: $264 · 2023: $411 · 2024: $266 · 2025: $61.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $719 · Education: $19.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $719.06 |
| Education | $19.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $223.32 | 2019-2025 | Farxiga, Lokelma, Brilinta |
| Amgen INC. | $209.85 | 2019-2024 | Tavneos, Krystexxa, Parsabiv |
| Alexion Pharmaceuticals, INC. | $175.91 | 2019-2023 | Ultomiris |
| Boston Scientific Corporation | $143.66 | 2023 | Avvigo Guidance System |
| Otsuka America Pharmaceutical, INC. | $141.77 | 2019-2025 | Jynarque |
| Baxter Healthcare | $130.88 | 2019 | |
| Vifor Pharma, INC. | $87.39 | 2020-2023 | Veltassa |
| Travere Therapeutics, INC. | $60.73 | 2024-2025 | |
| Horizon Therapeutics Plc | $57.36 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.20 | 2022-2024 | |
| Ultragenyx Pharmaceutical INC. | $41.56 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $39.37 | 2020-2021 | |
| Glaxosmithkline, LLC. | $34.89 | 2022-2023 | Benlysta |
| Opko Pharmaceuticals, LLC | $34.68 | 2021-2024 | Rayaldee |
| Lilly USA, LLC | $29.09 | 2024 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $27.55 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.99 | 2020 | |
| Vbi Vaccine (Delaware) INC. | $21.39 | 2022 | |
| Kyowa Kirin, INC. | $20.28 | 2023 | |
| Daiichi Sankyo INC. | $19.33 | 2020 | |
| Veloxis Pharmaceuticals, INC. | $17.40 | 2022 | |
| Kci USA, INC. | $17.29 | 2022 | |
| Global Blood Therapeutics, INC. | $16.49 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.19 | 2023 | Jardiance |
| Aurinia Pharma U.S., INC. | $15.81 | 2023 | Lupkynis |
| Merck Sharp & Dohme LLC | $15.60 | 2023 | Verquvo |
| Novo Nordisk INC | $14.47 | 2021 | |
| Akebia Therapeutics INC | $12.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Graham Byrum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.